1
|
Wang W, Jin W, Liu X, Zheng L. Circ_0002577/miR-126-5p/MACC1 axis promotes endometrial carcinoma progression by regulation of proliferation, migration, invasion, and apoptosis of endometrial carcinoma cells. Arch Gynecol Obstet 2022; 306:481-491. [PMID: 35103833 DOI: 10.1007/s00404-022-06412-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 01/04/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Endometrial carcinoma (EC) is a common female reproductive malignant tumor. Circular RNAs (circRNAs) have been reported to participate in tumorigenesis, including EC. Therefore, this study was designed to clarify the role and underlying molecular mechanisms of circ_0002577 in EC. METHODS The expression levels of circ_0002577, miR-126-5p, and metastasis associated in colon cancer 1 (MACC1) was determined by real-time quantitative polymerase chain reaction (RT-qPCR) assay. The protein expression was quantified by western blot assay. The proliferation of EC cells was assessed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazol-3-ium bromide (MTT) and colony-forming assays. The migration and invasion of EC cells was measured by transwell assay. The apoptosis was determined by flow cytometry assay. Dual-luciferase reporter assay and RNA pull-down assays were performed to confirm the relationship between miR-126-5p and circ_0002577 or MACC1. The influence of circ_0002577 inhibition on tumor growth was assessed by xenograft experiment. RESULTS Circ_0002577 and MACC1 were increased while miR-126-5p was decreased in EC tissues and cells. Loss-of-functional experiment revealed that silencing of circ_0002577 inhibited the proliferation, migration, and invasion while induced apoptosis of EC cells, which were overturned by overexpression of MACC1. The upregulation of miR-126-5p also impeded proliferation and mobility while induced apoptosis of EC cells. MiR-126-5p, negatively regulating MACC1 expression, was a functional target of circ_0002577 in EC cells. Moreover, we also confirmed that suppression of circ_0002577 repressed tumor growth in vivo. CONCLUSION The contributions of the circ_0002577 in EC were contributed to its interactions with miR-126-5p and MACC1, which offered a new perspective to the roles of circ_0002577 in EC.
Collapse
Affiliation(s)
- Wenzhi Wang
- Department of Gynaecology, Shaanxi Provincial People's Hospital, No. 256, Youyi West Road, Xi'an City, 710000, Shaanxi Province, China.
| | - Wen Jin
- Department of Gynaecology, Shaanxi Provincial People's Hospital, No. 256, Youyi West Road, Xi'an City, 710000, Shaanxi Province, China
| | - Xiaoying Liu
- Department of Gynaecology, Shaanxi Provincial People's Hospital, No. 256, Youyi West Road, Xi'an City, 710000, Shaanxi Province, China
| | - Lei Zheng
- College of Pharmacy, Xi'an Medical University, Xi'an, Shaanxi, China
| |
Collapse
|
2
|
Ribeiro R, Fontes Cintra G, Barrozo A, Tieko Tsunoda A, Pupo Nogueira A, Andreazza Laporte G, de Araújo RLC, Jara Reis R, Patury P, Reis RD, Affonso RJ, Moretti Marques R, Leal RMLV, Oliveira AF, Henrique Zanvettor P, de Oliveira Lopes FC, Arenhart Pessini S, Lopes A, de Azevedo RN, de Assis Gobetti G, Silva KFPE, Andrade CEMDC, Carneiro VCG, Fin FR, de Castilho TJC, Kwiatkowski FV, Simões JC, Foiato T, de Oliveira VR, Augusto Casteleins W, Filippi LT, Zanini LAG, de Maria Maués Sacramento R, de Souza RS, Castro Lanaze G, Barreto E, Fonteles Ritt G, Ziggiatti Güth G, de Sousa TA, Cruz RP, Schwengber A, Bocanegra RED, da Silva JPA, Tayeh MRA, Filho JDN, Gatelli CN, Adriano MG, Toniazzi Lissa F, de Oliveira Cucolicchio G, Loureiro CMB, Cunha JRD, Lourenço Lira D, de Araújo EO, de Resende FAM, Venâncio Pinto C, Mendes Medeiros G, Baiocchi G. Brazilian Society of Surgical Oncology guidelines for surgical treatment of endometrial cancer in regions with limited resources. J Surg Oncol 2019; 121:730-742. [PMID: 31845348 DOI: 10.1002/jso.25797] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 11/22/2019] [Indexed: 12/19/2022]
Abstract
BACKGROUND Approximately 70% of cancer-related deaths occur in low- and middle-income countries. In addition to social and racial inequalities, treatment options in these countries are usually limited because of the lack of trained staff and equipment, limited patient access to health services, and a small number of clinical guidelines. OBJECTIVES The Brazilian Society of Surgical Oncology developed this guideline to address these barriers and guide physicians treating patients with endometrial cancer (EC) in regions with limited resources and few specialized centers. METHODS The guideline was prepared from 10 January to 25 October 20192019 by a multidisciplinary team of 56 experts to discuss the main obstacles faced by EC patients in Brazil. Thirteen questions considered critical to the surgical treatment of these patients were defined. The questions were assigned to groups that reviewed the literature and drafted preliminary recommendations. Following a review by the coordinators and a second review by all participants, the groups made final adjustments for presentations in meetings, classified the level of evidence, and voted on the recommendations. RESULTS For all questions including staging, fertility spearing treatment, genetic testing, sentinel lymph node use, surgical treatment, and other clinical relevant questions, major agreement was achieved by the participants, always using accessible alternatives. CONCLUSIONS It is possible to provide adequate treatment for most EC patients in resource-limited areas, but the first option should be referral to specialized centers with more resources.
Collapse
Affiliation(s)
- Reitan Ribeiro
- Department of Surgical Oncology, Erasto Gaertner Hospital, Curitiba, Brazil
| | | | - Abner Barrozo
- Department of Surgical Oncology, Instituto Brasileiro de Controle de Câncer, São Paulo, Brazil
| | | | | | - Gustavo Andreazza Laporte
- Departament of Surgical Oncology, Santa casa de Porto Alegre/Santa Rita Hospital/Universidade Federal de ciências da Saúde de Porto Alegre, Porto Alegre, Brazil
| | | | - Rosilene Jara Reis
- Departament of Surgical Oncology, Santa casa de Porto Alegre/Santa Rita Hospital/Universidade Federal de ciências da Saúde de Porto Alegre, Porto Alegre, Brazil
| | - Patricia Patury
- Gynecologic Oncology Department, National Cancer Institute, Rio de Janeiro, Brazil
| | - Ricardo Dos Reis
- Gynecologic Oncology Department, Barretos Cancer Hospital, Barretos, Brazil
| | | | - Renato Moretti Marques
- Gynecologic Oncology Division, Oncologic Center, Albert Einstein Hospital, São Paulo, Brazil
| | | | | | | | | | - Suzana Arenhart Pessini
- Department of Gynecologic Oncology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.,Department of Gynecologic Oncology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - André Lopes
- Department of Gynecology, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil
| | | | | | | | | | | | - Fabio Roberto Fin
- Gynecologic Oncology Department, São Vicente Hospital, Curitiba, Brazil
| | | | | | - João Carlos Simões
- Department of Surgical Oncology, Mackenzie University Hospital, Curitiba, Brazil
| | - Tariane Foiato
- Department of Surgical Oncology, Cascavel Cancer Hospital, Castavel, Brazil
| | | | | | - Lucas Torelly Filippi
- Department of Surgical Oncology, Nossa Senhora da Conceição Hospital, Porto Alegre, Brazil
| | | | | | | | | | - Elio Barreto
- Department of Oncology, Onofre Lopes University Hospital, Natal, Brazil
| | | | | | | | - Ricardo Pedrini Cruz
- Department of Surgical Oncology, Nossa Senhora da Conceição Hospital, Porto Alegre, Brazil
| | - Alex Schwengber
- Department of Surgical Oncology, Ana Nery Hospital, Jacarezinho, Brazil
| | | | | | - Muhamed Read Ali Tayeh
- Department of Surgical Oncology, Materninade Marieta Konder Bornhausen Hospital, Itajaí, Brazil
| | | | | | | | | | | | | | | | | | | | | | - Cláudio Venâncio Pinto
- Department of Surgical Oncology, Centro de Câncer de Brasília (CETTRO), Brasilia, Brazil
| | | | - Glauco Baiocchi
- Department of Gynecologic Oncology, AC Camargo Cancer Center, São Paulo, Brazil
| |
Collapse
|
3
|
Giles SL, Imseeh G, Rivens I, ter Haar GR, Taylor A, deSouza NM. MR guided high intensity focused ultrasound (MRgHIFU) for treating recurrent gynaecological tumours: a pilot feasibility study. Br J Radiol 2019; 92:20181037. [PMID: 31084495 PMCID: PMC6592075 DOI: 10.1259/bjr.20181037] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 03/07/2019] [Accepted: 04/01/2019] [Indexed: 12/31/2022] Open
Abstract
OBJECTIVE To assess the feasibility of targeting recurrent gynaecological tumours with MR guided high intensity focused ultrasound (MRgHIFU). METHODS 20 patients with recurrent gynaecological tumours were prospectively scanned on a Philips/Profound 3 T Achieva MR/ Sonalleve HIFU system. Gross tumour volume (GTV) and planning target volume (PTV) were delineated on T 2W and diffusion-weighted imaging (DWI). Achievable treatment volumes that (i) assumed bowel and/or urogenital tract preparation could be used to reduce risk of damage to organs-at-risk (TVoptimal), or (ii) assumed no preparations were possible (TVno-prep) were compared with PTV on virtual treatment plans. Patients were considered treatable if TVoptimal ≥ 50 % PTV. RESULTS 11/20 patients (55%) were treatable if preparation strategies were used: nine had central pelvic recurrences, two had tumours in metastatic locations. Treatable volume ranged from 3.4 to 90.3 ml, representing 70 ± 17 % of PTVs. Without preparation, 6/20 (30%) patients were treatable (four central recurrences, two metastatic lesions). Limiting factors were disease beyond reach of the HIFU transducer, and bone obstructing tumour access. DWI assisted tumour outlining, but differences from T 2W imaging in GTV size (16.9 ± 23.0%) and PTV location (3.8 ± 2.8 mm in phase-encode direction) limited its use for treatment planning. CONCLUSIONS Despite variation in size and location within the pelvis, ≥ 50 % of tumour volumes were considered targetable in 55 % patients while avoiding adjacent critical structures. A prospective treatment study will assess safety and symptom relief in a second patient cohort. ADVANCES IN KNOWLEDGE Target size, location and access make MRgHIFU a viable treatment modality for treating symptomatic recurrent gynaecological tumours within the pelvis.
Collapse
Affiliation(s)
- Sharon L Giles
- The CRUK Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| | - Georgios Imseeh
- Department of Gynae-Oncology, The Royal Marsden Hospital, London, United Kingdom
| | - Ian Rivens
- Therapeutic Ultrasound, The Institute of Cancer Research, London, United Kingdom
| | - Gail R ter Haar
- Therapeutic Ultrasound, The Institute of Cancer Research, London, United Kingdom
| | - Alexandra Taylor
- Department of Gynae-Oncology, The Royal Marsden Hospital, London, United Kingdom
| | - Nandita M deSouza
- The CRUK Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| |
Collapse
|
7
|
Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings. Arch Gynecol Obstet 2011; 285:521-7. [PMID: 21779772 DOI: 10.1007/s00404-011-2004-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2010] [Accepted: 07/08/2011] [Indexed: 10/18/2022]
Abstract
PURPOSE The aim of this study was to determine whether a pre-intraoperative prognostic classification of endometrial cancer (EC) patients may accurately predict prognosis. METHODS Prognostic factors achievable before and during surgery (histotype, grade, myoinvasion, cervical spread, abdominal spread) were utilized to classify patients in low-risk (endometrial adenocarcinoma, grade 1-2, myoinvasion <50%, no evidence of abdominal spread), and in intermediate/high risk (serous papillary and clear cell, grade 3, myoinvasion >50%, cervical invasion, abdominal spread). Risk classification obtained pre-intraoperatively was compared with the classification obtained from definitive surgical-pathological assessment in 130 consecutive patients with EC treated with surgery. RESULTS Pre-intraoperative risk assessment correctly identified risk classification in 125 (96%) patients; sensitivity, specificity, PPV and NPV were 98%, 94%, 94%, and 98%, respectively. Median follow-up was 38 months (range 6-93), and 14 (10%) patients relapsed (median time 14 months, range 3-60). Relative risk of relapse was higher in intermediate/high-risk patients with both classifications (pre-intraoperative RR 3.37, CI 0.99-11.5; surgical-pathological RR 4.56, CI 1.2-17.3). As regards survival 11 patients have died, 6 due to endometrial cancer and 5 due to intercurrent disease. Five-years DFS according to pre-intraoperative assessment was 89% and 71% for low-risk and intermediate high-risk patients (p = 0.028), respectively; according to definitive assessment was 91% and 70% for low-risk and intermediate/high-risk patients (p = 0.009), respectively. CONCLUSION This classification, giving an accurate risk and prognostic estimate with parameters routinely utilized in clinical practice, may help the surgeon when undertaking the decision to perform limited or extended surgical staging according to tumor and patient characteristics.
Collapse
|